Viking Therapeutics
VKTX
372 hedge funds and large institutions have $1.88B invested in Viking Therapeutics in 2025 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 161 increasing their positions, 100 reducing their positions, and 99 closing their positions.
131% more call options, than puts
Call options by funds: $222M | Put options by funds: $96M
61% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 100
4.33% less ownership
Funds ownership: 73.61% → 69.28% (-4.3%)
9% less funds holding
Funds holding: 408 → 372 (-36)
34% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 99
43% less capital invested
Capital invested by funds: $3.3B → $1.88B (-$1.42B)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$30.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.9M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$21.6M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.3M |
| 5 |
Morgan Stanley
New York
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$173M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$54.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$27.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$24.9M |
| 5 |
PA
Perceptive Advisors
New York
|
-$15.4M |
VKTX Hedge Fund Activity: Q1 2025 in Review
372 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2025, worth a combined $1.88B — down 43% from $3.3B a quarter earlier.
Sellers outnumbered buyers: 99 funds closed out of VKTX and 65 opened new positions — a net loss of 34 holders — while 100 trimmed existing stakes and 161 added.
The largest buyer was JP Morgan Chase, adding an estimated $30.6M. The largest seller was Fidelity Investments, cutting an estimated $173M.
- 372 institutional investors held Viking Therapeutics (VKTX) as of Q1 2025, down from 408 in Q4 2024.
- Funds reported $1.88B of Viking Therapeutics stock for Q1 2025, down 43% quarter-over-quarter.
- 65 funds opened new Viking Therapeutics positions in Q1 2025 and 99 closed out, a net change of -34 holders.
- The largest Viking Therapeutics buyer in Q1 2025 was JP Morgan Chase, an estimated $30.6M added.
- The largest Viking Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $173M sold.
Based on aggregated 13F filings for Q1 2025.